EcoDrugPlus

Opioid Receptor, Delta 1a

Ensembl ID : ENSSMAG00000037219
Gene Symbol: OPRD1A
2 Cross references
191 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSSMAG00000001952
Gene Symbol: OPRD1B
3 Cross references
179 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSSMAG00000033971
Gene Symbol: OPRK1
3 Cross references
197 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSSMAG00000018843
Gene Symbol: OPRM1
3 Cross references
214 Possible Orthologues:

Oxytocin Receptor Like

Ensembl ID : ENSSMAG00000017218
Gene Symbol: OXTRL
2 Cross references
183 Possible Orthologues:

P21 Protein (Cdc42/rac)-Activated Kinase 4

Ensembl ID : ENSSMAG00000019623
Gene Symbol: PAK4
3 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSSMAG00000018658
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSSMAG00000014325
Gene Symbol: PPARG
3 Cross references
386 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha A

Ensembl ID : ENSSMAG00000018220
Gene Symbol: PPARAA
3 Cross references
383 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha B

Ensembl ID : ENSSMAG00000006814
Gene Symbol: PPARAB
3 Cross references
396 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta B

Ensembl ID : ENSSMAG00000019375
Gene Symbol: PPARDB
3 Cross references
392 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSSMAG00000008518
Gene Symbol: PIK3CA
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).